EZH2 and cancer: ARID1A mutations negatively impact DNA damage repair in cancer cells and while their role in regulating sensitivity to checkpoint inhibitors is unclear (62, 63), they have been also shown to sensitize cancer cells to PARP inhibition (64, 65) as well as to EZH2 inhibition (66).